<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>900</ReferenceId>
        <DateLastUpdated>2018-10-16-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11425742</PubmedId>
            <Abstract>Clostridium botulinum neurotoxin type A (BTx-A) is known to inhibit the release of acetylcholine at the neuromuscular junctions and synapses and to cause neuroparalysis and death. In this study, we have identified two monoclonal antibodies, BT57-1 and BT150-3, which protect ICR mice against lethal doses of BTx-A challenge. The neutralizing activities for BT57-1 and BT150-3 were 10(3) and 10(4) times the 50% lethal dose, respectively. Using immunoblotting analysis, BT57-1 was recognized as a light chain and BT150-3 was recognized as a heavy chain of BTx-A. Also, applying the phage display method, we investigated the antibodies' neutralizing B-cell epitopes. These immunopositive phage clones displayed consensus motifs, Asp-Pro-Leu for BT57-1 and Cys-X-Asp-Cys for BT150. The synthetic peptide P4M (KGTFDPLQEPRT) corresponded to the phage-displayed peptide selected by BT57-1 and was able to bind the antibodies specifically. This peptide was also shown by competitive inhibition assay to be able to inhibit phage clone binding to BT57-1. Aspartic acid (D(5)) in P4M was crucial to the binding of P4M to BT57-1, since its binding activity dramatically decreased when it was changed to lysine (K(5)). Finally, immunizing mice with the selected phage clones elicited a specific humoral response against BTx-A. These results suggest that phage-displayed random-peptide libraries are useful in identifying the neutralizing epitopes of monoclonal antibodies. In the future, the identification of the neutralizing epitopes of BTx-A may provide important information for the identification of the BTx-A receptor and the design of a BTx-A vaccine.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>3201-7</ArticlePages>
            <ArticleTitle>Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>H C</ForeName>
                </Author>
                <Author>
                    <LastName>Yeh</LastName>
                    <ForeName>C T</ForeName>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Y L</ForeName>
                </Author>
                <Author>
                    <LastName>Tarn</LastName>
                    <ForeName>L J</ForeName>
                </Author>
                <Author>
                    <LastName>Lung</LastName>
                    <ForeName>C C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Preventive Medicine, National Defense Medical Center, San-Hsia, Taiwan. hancw@pchome.com.tw.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Antibodies, Monoclonal;Epitopes, B-Lymphocyte;Peptide Library;Peptides;Botulinum Toxins, Type A</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Bacterial(biosynthesis; immunology); Antibodies, Monoclonal(biosynthesis; immunology); Botulinum Toxins, Type A(chemistry; genetics; immunology); Botulism(microbiology; prevention &amp; control); Clostridium botulinum(immunology); Enzyme-Linked Immunosorbent Assay; Epitopes, B-Lymphocyte(chemistry; genetics; immunology); Immunization; Immunoblotting; Mice; Mice, Inbred ICR; Molecular Mimicry; Molecular Sequence Data; Neutralization Tests; Peptide Library; Peptides(chemical synthesis; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>67</Volume>
                <Issue>7</Issue>
                <Title>Applied and environmental microbiology</Title>
                <Issn>1098-5336</Issn>
                <MedlineTa>Appl Environ Microbiol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>P4M</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>KGTFDPLQEPRT</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is a mimotope of:</RelatedObjectType>
                    <RelatedObject>
                        <AccessionSequenceMolecule>
                            <ChemicalType>Protein</ChemicalType>
                            <Molecule>
                                <GenBankId>Q3LRX9</GenBankId>
                            </Molecule>
                            <SourceOrganismId>1491</SourceOrganismId>
                        </AccessionSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>31069</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This mimotope was identified using a phage display library.  It is a mimotope of an epitope from the light chain of Clostridium botulinum neurotoxin A.  Eight phage clones were found to have significant reactivity with the monoclonal antibody.  The binding motif D-P-L was found in phage clones PC57-3, -4, -9, and -10; the binding motif D-A-L was found in phage clones PC57-6 and -7; and the binding motif D-V-L/F was found in phage clones PC57-5 and -8.  Alignment of the phage-displayed peptide sequences with the protein sequence of Clostridium botulinum neurotoxin A revealed that there was no significant homology between them, signifying that the epitope is a mimotope. Further demonstration of this is ability of the peptide to mimic the light chain immunogenically.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>10161</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>KGTFDPLQEPRT</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P4M</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ObjectLibrary>
                                        <DisplaySystemType>Phage display</DisplaySystemType>
                                    </ObjectLibrary>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Mice were immunized on days 0, 14, 28, and 42 with 10^12 pfu of phage particles.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In order to evaluate the immunogenicity of the phage-displayed peptide, peptide-expressing phage particles were injected into mice. and the response against the BoNT/A toxin was analyzed. The specificity of the antibody induced by the peptide was further demonstrated by immunoblotting analysis to be directed to the light chain of BoNT/A, as was the parental antibody that selected the immunogenic peptide.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>BONT/A toxin</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <BCellId>10156</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This mAb, showed to be specific for the light chain of BoNT/A, is shown to specifically recognize a phage clone carrying this peptide. In order to verify that the phage-displayed peptide sequence was recognized by the monoclonal antibody, the peptide was synthesized in multiple antigenic peptide form and assayed for binding. The monoclonal antibody bound the peptide in a concentration-dependent manner, and competed for binding with the phage-borne peptide. It was also shown that the Aspartic acid in position five was critical for binding.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT57-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>P4M</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>KGTFDPLQEPRT</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>10154</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>30</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>When incubated with Clostridium botulinum neurotoxin A, the mimotope-specific monoclonal antibody BT57-1 showed protective capacity to lethality in ICR mice.  The BT57-1 monoclonal antibody protected 6/6 mice from 10&lt;sup&gt;2&lt;/sup&gt; 50% lethal doses; 6/6 mice from 10&lt;sup&gt;3&lt;/sup&gt; 50% lethal doses, 2/6 mice from 10&lt;sup&gt;4&lt;/sup&gt; 50% lethal doses; 1/6 mice from 10&lt;sup&gt;5&lt;/sup&gt; 50% lethal doses; and 0/6 mice from 10&lt;sup&gt;6&lt;/sup&gt; 50% lethal doses.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT57-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>BONT/A toxin</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P5M</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>MCWDCTLHARSD</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is a mimotope of:</RelatedObjectType>
                    <RelatedObject>
                        <AccessionSequenceMolecule>
                            <ChemicalType>Protein</ChemicalType>
                            <Molecule>
                                <GenBankId>Q3LRX9</GenBankId>
                            </Molecule>
                            <SourceOrganismId>1491</SourceOrganismId>
                        </AccessionSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>41209</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This mimotope was identified using a phage display library.  It is a mimotope of an epitope from the heavy chain Clostridium botulinum neurotoxin A.  Six phage clones were found to have significant reactivity with the monoclonal antibody.  The binding motif of the antibody BT150-3 was shown to be C-X-D-C. This motif was exhibited in all six immunopositive phage clones    Alignment of the phage-displayed peptide sequences with the protein sequence of Clostridium botulinum neurotoxin A revealed that there was no significant homology between them, signifying that the epitope is a mimotope.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2B</LocationOfData>
                        <BCellId>1278145</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q45894.3</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This mAb, showed to be specific for the heavy chain of BoNT/A, is shown to specifically recognize a phage clone carrying this peptide. The monoclonal antibody bound the peptide-phage in a concentration-dependent manner.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT150-3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>P5M</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>MCWDCTLHARSD</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1278144</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q45894.3</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>30</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>70</ResponseFrequency>
                            <AssayComments>When incubated with Clostridium botulinum neurotoxin A, the mimotope-specific monoclonal antibody BT57-1 showed protective capacity to lethality in ICR mice.  The BT105-3 monoclonal antibody protected 6/6 mice from 10&lt;sup&gt;2&lt;/sup&gt; 50% lethal doses; 6/6 mice from 10&lt;sup&gt;3&lt;/sup&gt; 50% lethal doses, 6/6 mice from 10&lt;sup&gt;4&lt;/sup&gt; 50% lethal doses; 3/6 mice from 10&lt;sup&gt;5&lt;/sup&gt; 50% lethal doses; and 0/6 mice from 10&lt;sup&gt;6&lt;/sup&gt; 50% lethal doses.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT105-3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>BONT/A toxin</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>BoNT/A1 Light chain</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNK</LinearSequence>
                        <StartingPosition>2</StartingPosition>
                        <EndingPosition>448</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P10845.4</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1491</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>47589</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1278143</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>KGTFDPLQEPRT</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P4M</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ObjectLibrary>
                                        <DisplaySystemType>Phage display</DisplaySystemType>
                                    </ObjectLibrary>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Mice were immunized on days 0, 14, 28, and 42 with 10^12 pfu of phage particles.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In order to evaluate the immunogenicity of a phage-displayed mimotope peptide, peptide-expressing phage particles were injected into ICR mice and the response against the BoNT/A toxin was analyzed in ELISA. All the mice generated a specific response.  The specificity of the antibody induced by the peptide was further demonstrated by immunoblotting analysis to be directed to the light chain of BoNT/A, as was the parental mAb (BT57-1) that selected the immunogenic peptide.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type A</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1278072</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>30</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>When incubated with Clostridium botulinum neurotoxin A, the anti-light chain BT57-1 showed protective capacity to lethality in ICR mice. The BT57-1 monoclonal antibody protected 6/6 mice from 10&lt;sup&gt;2&lt;/sup&gt;  50% lethal doses; 6/6 mice from 10&lt;sup&gt;3&lt;/sup&gt; 50% lethal doses, 2/6 mice from 10&lt;sup&gt;4&lt;/sup&gt; 50% lethal doses; 1/6 mice from 10&lt;sup&gt;5&lt;/sup&gt; 50% lethal doses; and 0/6 mice from 10&lt;sup&gt;6&lt;/sup&gt; 50% lethal doses.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT57-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type A</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1278073</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μgg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunoblotting showed that the BoNT/A specific monoclonal antibody  BT57-1 bound to intact Clostridium botulinum neurotoxin A, as well as to the light chain of the neurotoxin.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT57-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type A</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>BoNT/A1 Heavy chain</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIR</LinearSequence>
                        <StartingPosition>449</StartingPosition>
                        <EndingPosition>948</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P10845.4</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1491</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>2775</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1278153</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunoblotting showed that the BoNT/A specific monoclonal antibody  BT105-3 bound to intact Clostridium botulinum neurotoxin A, as well as to the heavy chain of the neurotoxin.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT105-3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type A</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1278152</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P10845.4</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1491</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>BoNT/A toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 25 μg protein in adjuvant (CFA for the 1st, IFA for the other 2 doses); 3 weeks later one dose of 50μg without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with formalin-inactivated Clostridium botulinum neurotoxin A. Monoclonal antibodies were generated from the spleens of immunized mice, which were fused with NS1/1-Ag4-1 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>30</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>70</ResponseFrequency>
                            <AssayComments>When incubated with Clostridium botulinum neurotoxin A, the anti-heavy chain BT105-3 showed protective capacity to lethality in ICR mice. The monoclonal antibody protected 6/6 mice from 10&lt;sup&gt;2&lt;/sup&gt;  50% lethal doses; 6/6 mice from 10&lt;sup&gt;3&lt;/sup&gt; 50% lethal doses, 6/6 mice from 10&lt;sup&gt;4&lt;/sup&gt; 50% lethal doses; 3/6 mice from 10&lt;sup&gt;5&lt;/sup&gt; 50% lethal doses; and 0/6 mice from 10&lt;sup&gt;6&lt;/sup&gt; 50% lethal doses.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BT105-3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Botulinum neurotoxin type A</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P10845.4</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1491</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

